Methods

Study Background
Seventeen sites participated in the study. The first 3 patients enrolled at each site were nonrandomized training cases and were treated with TDR (51 enrolled, 50 treated). These patients were monitored in exactly the same clinical and radiographic manner as the randomized patients. Subsequent patients at each site were randomized in a 2:1 ratio of TDR to circumferential fusion. Patients were blinded to randomization until immediately postsurgery. Two hundred forty-two patients were randomized and treated. Six patients were treated off protocol based on intraoperative decisions made by their surgeons. Two of the cases involved unrecognized spondylotic defects not recognized preoperatively. One patient randomized to TDR was treated with TDR despite the index-level pars defect. The second patient was randomized to fusion, and the surgeon was not comfortable fusing adjacent to the newly recognized open-pars segment, so he performed a 2-level fusion. Four cases were administrative errors in that patients with 2-level involvement were scheduled for 2-level surgery but never disenrolled when the second level was indicated preoperatively. As these 6 patients were all enrolled with known exclusions, they were classified as "treated off protocol" and their data were not added to the study database.
An additional exclusion criterion relating to patient vertebral endplate size was added after the study began, so that in small-framed patients, investigators were asked to evaluate axial CT scans and exclude patients whose vertebral endplate dimensions were less than 34.5 mm in the mediolateral direction and/or less than 27 mm in the anteroposterior direction (the exact size of the smallest available ProDisc-L endplate).
The surgical procedure has been described in detail elsewhere. 11 The fusion group received commercially available femoral ring allograft and posterolateral fusion with autogenous iliac crest bone graft in combination with pedicle screws. Although iliac crest harvest might be responsible for persistent outcome differences between the groups, this was not observed. No adverse events related to graft harvest (hematoma or infection) were encountered. No structural bone grafts were needed, as only cancellous bone was required for posterolateral onlay fusion, limiting the scope of crest violation, and graft was generally harvested through the same skin incision as the fusion.
No adverse events specific to iliac crest harvest were recorded. Although iliac crest pain certainly occurred, it was not believed to exert a clinically significant effect on the fusion patient's postoperative course. Even if iliac crest site pain contributed to increased pain (VAS) or impairment (ODI), this additional burden would normally be expected to resolve within a few weeks or months. At the 2-year and certainly the 5-year follow-up, pain from the iliac crest donor site would be expected to be insignificant.
Patients in all cohorts were evaluated preoperatively and at 6 weeks and 3, 6, 12, 18, and 24 months postoperatively. After completing 24 months of follow-up, patients were asked to consent to additional follow-up at 36, 48, and 60 months. At each follow-up visit, physical and neurological examinations, radiography studies, and patient self-assessments were conducted. The self-assessments included the ODI, 7 the SF-36, pain intensity on a 100-mm VAS (VAS pain), patient satisfaction (VAS satisfaction), and whether the patient would have the same surgery again. For the purposes of FDA evaluation, a composite binary end point was defined in the protocol. The composite measure, termed "statistical success," encompassed the primary effectiveness and safety criteria summarized in Table 1 . A patient was classified as a statistical success if and only if all criteria specified in the table were met.
Radiographs (anteroposterior and lateral, flexion and extension) were obtained preoperatively and at each follow-up visit, with patients standing when clinically possible to ensure their natural anatomical position. An independent radiographic reviewer (Medical Metrics, Inc.) who was blinded to the particular patient history or outcome and had no contact with any investigator both measured and analyzed radiographic data.
Statistical Analysis
Before initiating the study, sample size for the 24-month follow-up was estimated using the original approximate calculation of Blackwelder.
1 A Type I error of 5% (1-sided) and 80% power was chosen, assuming an 85% chance of statistical success at 24 months in each group. The calculated sample size was 144 and 72 for the TDR and fusion groups, respectively, and 255 total (170 TDR and 85 fusion control) with a correction for 15% attrition.
The noninferiority hypothesis was based on an exact 95% 1-sided upper confidence bound for the difference in overall statistical success probabilities between TDR and fusion groups. If the upper bound was within the noninferiority margin (12.5%), then TDR was considered noninferior to fusion. All patients with available information at the 24-and 60-month follow-up visits were included in the noninferiority analysis, with the exception of the 6 protocol violators (Table 2) .
Clinical outcomes as measured by the ODI, the VAS pain, the SF-36, the VAS satisfaction, surgery again, and adverse event rates are reported using a per-protocol analysis. This analysis excluded patients at a given follow-up if the intended treatment was significantly altered-specifically, the 6 patients treated off protocol, TDR patients who underwent index-level revisions, and fusion patients who underwent index-level revisions (excluding hardware removal after successful fusion). The per-protocol analysis represents data requested by and reported to the FDA. Note, however, that all patients were included in an intentto-treat analysis and will be discussed below.
Demographic data were compared in the TDR versus fusion cohorts using the Wilcoxon rank-sum test or Fisher exact test. Secondary clinical outcomes were compared in TDR versus fusion patients using 2-sample t-tests (percent improvements in ODI, VAS pain, SF-36, and VAS satisfaction) or Fisher exact test (components of statistical success, narcotics use, and recreational status). Data at 2 and 5 years after treatment were compared with baseline data within each treatment group using the paired t-test. Significance was set at p < 0.05. Table 2 summarizes patient enrollment and followup. Follow-up rates are reported for all patients who were evaluated at that follow-up visit, regardless of whether their data set was complete. Overall patient follow-up was 97.0% of 236 patients at 2 years and 81.8% of 236 patients at 5 years. Complete radiographic data sets were available for 72.9% of the patients. Demographics for patients enrolled and treated in the IDE study are shown in Table 3 . There were no statistically significant differences between the fusion and TDR patients in any of the demographic characteristics, including age, body mass index, race, smoking status, baseline ODI, or percentage of patients who had prior surgical treatment.
Results
Intraoperative data were previously reported in detail. 11 The TDR group underwent an anterior approach, whereas the fusion group underwent anterior and posterior approaches. The mean intraoperative time was significantly shorter in the TDR group than in the fusion group (121.7 vs 229.0 minutes, p < 0.0001). The mean estimated blood loss was lower in the TDR group than in the fusion control group (203.7 vs 466.8 ml, p < 0.0001). Duration of hospital stay was also statistically significantly shorter in the TDR group (3.5 vs 4.3 days, p < 0.0001) than in the control group.
Primary Clinical Outcomes
Composite End Point. For FDA evaluation, a composite outcome was determined based on criteria in Table 1 , in which patients had to satisfy all criteria outlined to be a statistical success. At 2 years posttreatment, 63.5% of 148 TDR patients and 45.1% of 71 fusion patients achieved overall statistical success, supporting the hypothesis that TDR was noninferior to fusion with a 12.5% margin (p < 0.0099). Although the study was not designed to show a difference, a statistically significant difference in success rates between the TDR and fusion groups at 2 years was found using a 1-sided Fisher exact test (p = 0.0053). At 5 years posttreatment, 53.7% of 134 TDR patients and 50.0% of 52 fusion patients were classified as statistical successes. The primary hypothesis of our study-that TDR was noninferior to fusion-was supported with these 5-year data using a 12.5% margin (p = 0.0236). To evaluate impact on results, which included any missing data, an intent-to-treat analysis was performed and included protocol violators as well as last available visit data. Noninferiority was still demonstrated while including all of these patients (34 [42.5%] of 80 patients for fusion and 84 [51.8%] of 162 patients for TDR, p = 0.0008). Superiority of TDR over fusion using this composite outcome success model was not demonstrated at 5 years (p = 0.7438).
Results regarding each component of the composite end point are detailed in the sections that follow. Patients in whom secondary surgeries had failed were excluded from determinations of ODI, SF-36, neurological, and radiographic success outcomes because they no longer had the original treatment.
Oswestry Disability Index. Preoperative ODI scores of 63% were similar between fusion and TDR patients (Table 4) . At 2 years posttreatment, ODI scores improved significantly as compared with baseline in both fusion and TDR patients (p < 0.0001). The mean ODI score percentage improvements were greater in TDR patients than in fusion patients at 2 years (p = 0.0550). A significantly greater number of TDR patients had ≥ 15% improvement in the ODI score at 2 years (77.2%) compared with fusion patients (64.8%; p < 0.05). Similarly, at 2 years, a significantly greater percentage of TDR patients had a ≥ 15-point improvement in the ODI score (67.8% of TDR patients and 54.9% of fusion patients, p = 0.0449). At 5 years, both treatment groups maintained significant improvements in the ODI score compared with baseline (p < 0.0001). The mean ODI score improvements for TDR patients were maintained from 2 to 5 years, whereas mean ODI improvements for fusion patients were similar to those for TDR patients at 5 years (p = 0.4552). The majority of patients in both treatment groups had ODI score improvements ≥ 15% at 5 years (76.5% of fusion patients, 78.6% of TDR patients, p = 0.8417) or ≥ 15 points at 5 years (62.8% of fusion patients, 74.6% of TDR patients, p = 0.1427). Of the patients who had ODI score improvements ≥ 15% at 2 years compared with baseline, a substantial proportion of patients maintained ≥ 15% improvement from baseline at 5 years (86.1% of fusion patients and 89.1% of TDR patients).
36-Item Short Form Health Survey PCS.
The mean baseline SF-36 PCS was similar in TDR and fusion patients (Table 5 ). Both treatment groups had improvements in the SF-36 PCS at 2 and 5 years of follow-up, compared with baseline (p < 0.0001). The TDR patients experienced significantly greater improvements in SF-36 PCSs at 2 years than did fusion patients (p = 0.0363); a similar trend was observed at 5 years (p = 0.1677). At 2 years, 70.0% of fusion patients and 79.2% of TDR patients had maintained or improved SF-36 PCSs (p = 0.0943). At 5 years, the majority of patients maintained or improved SF-36 PCSs compared with baseline (74.0% of fusion patients and 81.3% of TDR patients, p = 0.3054). Of the patients who maintained or improved SF-36 PCSs at 2 years compared with baseline, a substantial proportion of them also maintained or improved scores at 5 years compared with baseline (81.1% of fusion patients and 88.2% of TDR patients).
Neurological Success. Neurological success was defined as the maintenance or improvement of patient responses to all neurological criteria: sensory and motor status, reflexes, and straight-leg test. At 2 years posttreatment, the TDR group was statistically superior to the fusion group, with 91.2% success (135 of 148 patients) compared with 81.4% (57 of 70 patients), respectively (p = 0.0341). Compared with rates at 2 years, the percentage of patients achieving overall neurological success at 5 years was similar in the TDR patients (111 [88.8%] of 125 patients) and increased in fusion patients (43 [89.6%] of 48 patients); there was no significant difference in neurological success between TDR and fusion patients at 5 years posttreatment (p = 1.0000). Of the patients who had neurological success at 2 years, 90.5% of fusion patients and 93.0% of TDR patients had neurological success at 5 years.
Radiographic Success. The composite statistical success definition includes 6 radiographic outcomes. Five of these components refer to qualitative evaluations of device migration, device subsidence, disc height maintenance, fusion status, and radiolucency (Table 6 ). The results presented below refer to patients with available radiographs for the 5-year follow-up visit. Although clinical follow-up at 5 years was 81.8% of 236 patients, only 72.9% of the patients had complete radiographic data sets and are included in this subanalysis. In the remaining patients, radiographs were deemed not satisfactory for digital analysis.
Three TDR patients demonstrated radiographic evi- dence of device migration at 5 years; in all 3 of these patients, radiographic evidence of migration was first noted at the 3-month follow-up visit. There were 2 cases of TDR radiographic subsidence by the 5-year follow-up. In one of these patients, the radiographic subsidence was present at the 3-month visit. In the other patient, there was evidence of radiolucency prior to the 2-year visit; radiographs at the 5-year visit showed evidence of TDR subsidence with a concomitant decrease in disc height. There were no additional cases of radiolucency, subsidence, or disc height changes in TDR patients with available radiographs at 5 years. At 5 years, none of the fusion patients with available films demonstrated device migration. Four fusion patients had a disc height decrease more than 3 mm (due to subsidence or graft settling) at the 5-year visit. No cases of subsidence (that is, violation of vertebral endplates > 3 mm) or radiolucency were observed in any of the fusion patients with available radiographs at 5 years.
Radiographic films available at 5 years indicated that 2 fusion patients had failed to attain more than 50% trabecular bridging bone, although none of the fusion patients required a secondary procedure for clinical pseudarthrosis. Radiographic fusion rates were 97.1% and 95.8% of fusion patients with available films at 2 and 5 years, respectively. All fusion patients had less than 3 mm of translation and less than 5° of flexion and extension rotation on 5-year radiographs.
The sixth radiographic outcome was flexion and extension ROM, defined in the TDR group as restoration to a normal ROM at the implanted level (for L3-4 and L4-5, between 6° and 20°; for L5-S1, between 5° and 20°). The ROM criterion was met by 93.7% of the TDR patients at 2 years posttreatment and 91.9% of them at 5 years. The mean flexion and extension ROM in the TDR group was 7.7° ± 4.7° at 2 years and 7.2° ± 4.1° at 5 years.
Index-Level Secondary Surgeries. Secondary surgeries at the index level occurred in 9 fusion patients (12%) and 13 TDR patients (8%) by the end of the 5-year study. Details regarding these surgeries, as well as information related to their classification with respect to the primary end point (that is, device success), are provided below.
Device success was defined as the absence of any reoperation to modify or remove implants and no need for supplemental fixation. At 2 years, device success was achieved in 96.3% of the 161 TDR patients and 97.3% of the 75 fusion patients (p = 1.0000). Six TDR patients (3.7%) were considered to have device failures at 2 years: 2 cases of polyethylene migration due to extreme trauma (discussed below), 1 polyethylene inlay migration within 48 hours that was not locked correctly at the time of implantation, and 1 case of implant migration as a result of oversizing. The implant migration event led us to add an exclusion criterion requiring a minimum vertebral body dimension less than 34.5 mm in the mediolateral direction and/or less than 27 mm in the anteroposterior direction (the exact size of the smallest available ProDisc-L endplate), as measured on a preoperative axial CT scan obtained in small-stature patients. This size exclusion was not required for any other potential patient in the randomized study. The 2 remaining TDR device failures that occurred by the 2-year follow-up included 1 case of technical error in which the inlay was inserted backward, requiring reoperation and reinsertion of the inlay, and 1 case in which a patient required supplemental posterior fixation due to unresolved pain. One additional TDR patient had secondary surgery at the index level but was not considered to have device failure. This patient underwent hemilaminotomy and discectomy with nerve root decompression that did not require modification or explantation of the device. One case of traumatic polyethylene component extrusion occurred at L5-S1 in a 33-year-old male powerlifter who worked out regularly, lifting 700-lb weights, and was discovered at the 18-month postoperative visit. It had occurred several weeks earlier when the previously asymptomatic patient experienced acute pain while working out. He sustained an iliac vein laceration during revision surgery and a postoperative compartment syndrome with complications. His device implantation was revised to a fusion.
The second case of traumatic polyextrusion occurred at L5-S1 in a 41-year-old man who was involved in a motor vehicle accident 23 months after implantation. While experiencing increased back pain after the accident, this patient fell in the shower, causing a further increase in pain. As a result of these sequential traumas, the polyethylene component was noted to have extruded anteriorly. Device implantation was revised to a 360° fusion, and the patient did not show significant clinical improvement from his preoperative status.
At 2 years posttreatment, 2 fusion patients (2.7%) were considered to have device failures when both patients had unresolved pain requiring reoperation. By 2 years posttreatment, another 2 fusion patients underwent hardware removal for hardware-related pain and were not considered to have device failures.
At 5 years posttreatment, device success was achieved in 93.2% of 161 TDR patients and 93.3% of 75 fusion patients (cumulative). The 5 TDR patients who were classified as having device failures between 3 and 5 years of follow-up underwent supplemental fixations at the index level due to pain, and the fixations were addressed posteriorly. An additional TDR patient underwent secondary surgery at the index level between 3 and 5 years of follow-up and was not considered to have device failure; this patient underwent hemilaminectomy nerve decompression along with the removal of a small disc fragment at the index level.
Between 3 and 5 years of follow-up, 3 fusion patients were considered to have device failures because they had unresolved pain that required reoperation (6.7% cumulative). Two additional fusion patients had index-level sur- geries but were not considered to have device failures because the device or intended treatment was not altered in any way. These 2 fusion patients underwent routine hardware removal for pain; the fusion mass in these patients was confirmed to be solid during the surgery.
Secondary Clinical Outcomes
VAS Pain. A summary of VAS pain assessment is provided in Table 7 . Both TDR and fusion groups demonstrated significant improvements in VAS pain scores at 2 and 5 years posttreatment compared with baseline (p < 0.0001). The mean percentage improvements in VAS pain were similar in TDR and fusion patients at the 2-and 5-year follow-up visits.
VAS Satisfaction. Patients indicated their satisfaction with treatment on a 100-mm VAS. At 2 years posttreatment, mean VAS satisfaction was statistically greater in TDR patients than in fusion patients (76.7 ± 29.2 vs 67.3 ± 31.5, respectively, p = 0.0150). At 5 years posttreatment, TDR patient satisfaction was similar to that at 2 years, whereas mean VAS satisfaction in fusion patients increased to a level that was similar to that in TDR patients (TDR: 78.3 ± 27.1, fusion: 78.1 ± 26.7, p = 0.6199). When asked if they would have the same surgery again, 82.5% of TDR patients and 68.0% of fusion patients responded "yes" at 5 years posttreatment; this rate was not significantly different between the groups (p = 0.1634).
Recreational Activity Status. At baseline, a similar proportion of TDR and fusion patients reported that they engaged in recreational activity (42.2% of 161 TDR patients and 49.3% of 75 fusion patients). At 2 years, the recreational status improved for both groups and trended toward a greater percentage of TDR patients engaging in recreational activity compared with fusion patients (88.4% of 147 TDR patients vs 78.3% of 69 fusion patients, p = 0.0640). At 5 years, the recreational activity status for both treatment groups had improved compared with baseline and was not significantly different (82.4% of 125 TDR patients vs 90.0% of 50 fusion patients, p = 0.2526).
Narcotic Use. At the time of surgery, 76% of fusion patients and 84% of TDR patients had used narcotics as a form of prior conservative treatment. At 2 years (42.5% of 70 fusion patients and 44.6% of 148 TDR patients) and 5 years (40.0% of 50 fusion patients and 38.4% of 125 TDR patients), the percentage of patients taking narcotics had decreased from baseline.
Alternate Analyses
While reviewing the study data, an alternate analysis was requested by the FDA to incorporate changes to the definition of statistical success that was not part of the original study protocol. This modified definition of statistical success was identical to that described in Table 1 , except that the condition for ODI improvement from baseline was 15 points (instead of 15%) and the condition for ROM success was any increase in ROM from baseline for TDR patients (rather than a return to a normal range). The FDA also requested a more conservative noninferiority margin of 10%. Using this alternate definition, we calculated that 40.8% of fusions and 53.4% of TDRs were statistical successes at 2 years and 41.1% of fusions and 48.1% of TDRs were statistical successes at 5 years. Statistical noninferiority (10% margin) was demonstrated at both follow-up periods using this alternate definition (p < 0.05).
We also conducted an intent-to-treat analysis for the 5-year exploratory clinical outcomes (Table 8 ). In the intent-to-treat analysis, we compared ODI, SF-36, and VAS pain scores at the 5-year follow-up in patients randomized to the TDR or fusion group, regardless of the type of intervention that was actually administered. This analysis included the 6 protocol violators during the index procedure (5 randomized to fusion, 1 randomized to TDR), as well as 11 TDR patients and 5 fusion patients who had device failures by 5 years. We also evaluated patients with missing data at the 5-year follow-up using the last observation carried forward (LOCF) method. All of these patients were included in the intent-to-treat analysis. No differences in the trends were observed in the intent-totreat analyses compared with those observed in the perprotocol analysis.
Adverse Events
On completion of the study, the number of adverse events reported per patient was similar for the fusion and TDR treatment groups (5.1 and 5.4 per patient, respectively, p = 0.5072). However, the fusion group had a significantly greater number of reported severe or lifethreatening adverse events compared with the TDR group (0.58 and 0.38 per patient, respectively, p = 0.0364).
Complications during the index surgery included 2 fusion group patients who experienced clinically signifi- cant blood loss (> 1500 ml) and 2 additional patients in the fusion group who experienced dural tears. None of these complications resulted in clinical sequelae. Postoperatively, retrograde ejaculation was reported in 1 fusion and 2 TDR patients. No infections were reported in the TDR group, and 2 posterior wound infections were reported in the fusion group. Deep venous thrombosis developed after surgery in 3 patients (2 TDR and 1 fusion) and was successfully treated medically. One TDR patient (0.6%) experienced clinically significant blood loss (> 1500 ml) during revision surgery. At 5 years posttreatment, 5 deaths had occurred (1 fusion and 4 TDR patients), all for reasons unrelated to the surgery or implants.
Discussion
This paper builds on results of a 2-year FDA IDE study for ProDisc-L and continues the follow-up of investigational (TDR) and control (fusion) cohorts through a 5-year postapproval study. The primary hypothesis of this multicenter, prospective randomized trial was supported at both 2 and 5 years posttreatment, allowing us to conclude that TDR is noninferior to fusion. Although the study was not designed as a superiority study, a significant difference favoring TDR was found in statistical success rates at 2 years. In addition to the primary outcome, exploratory analyses led to several conclusions. Both TDR and fusion patients in whom an average of 9 months of prior conservative care had failed showed improved clinical outcomes at the 2-and 5-year followups as compared with baseline. At 2 years, TDR patients showed statistically superior results in mean clinical outcomes such as ODI improvement, neurological success, and radiographic maintenance of disc height. The mean clinical outcomes in TDR patients held steady from 2 to 5 years and maintained that improvement compared with baseline. Fusion patients experienced further improvement in mean clinical outcomes from 2 to 5 years, with mean outcomes reaching levels similar to those observed for the TDR patients at 5 years.
An alternate analysis suggested by the FDA, after the study was underway, required a 15-point ODI improvement rather than 15% improvement from baseline and changed the definition of ROM success. Although the hard data remain exactly the same, this change in the semantics of success highlights the difficulty in interpreting complex success criteria. Most clinicians would be much more comfortable with an ROM success definition requiring a return to a normal range (the original definition) rather than an increase in the range (for example, a meaningless increase from 0 to 1°), as imposed by the FDA; however, both are presented.
In the current study, a successful fusion status required strong evidence of fusion, that is, more than 50% trabecular bridging bone or bone mass maturation, increased or maintained bone density at the site, and no visible gaps in the fusion mass. Using these strict radiographic criteria, we calculated a 97.1% fusion rate at 2 years and 95.8% at 5 years in patients with DDD in whom conservative treatment had failed. These fusion rates compare favorably with those previously reported for instrumented fusion in patients undergoing treatment for DDD in prospective randomized studies (73%-95%). [3] [4] [5] 10 It is noteworthy that patients in the current study received femoral ring allograft and autogenous iliac crest bone graft but no bone morphogenetic protein and that fusion rates in this series of patients were higher than those reported in prospective randomized studies evaluating bone morphogenetic protein in cases of single-level DDD (for example, 88% reported by Dimar et al. 4 and 91% reported by Burkus et al. 2 ). These findings further support the quality of surgical treatment provided to the control group. Contrary to increasingly strong evidence in the scientific literature supporting the effectiveness of both arthroplasty and fusion in appropriately selected patients, recent surgical approval policies by insurance payers have become narrower, limiting coverage for reconstructive spine surgery in patients who are experiencing persistent functional disability as a result of mechanical DDD. Our results combined with other strong scientific evidence in the peer-reviewed literature indicate a need to reconsider this conservative posture. In the current study, highly disabled patients with mechanical DDD, in whom conservative treatment had failed for at least 6 months, were treated with spinal fusion or TDR. This population was carefully selected using strict inclusion and exclusion criteria. Not only did patients in both treatment groups experience significant improvements in measurable clinical outcomes, such as the ODI score and VAS pain, but there were also substantial improvements in functional status. Specifically, over 80% of patients in this study experienced improvements in recreational status that were maintained 5 years after the index surgery, indicating substantial improvements in their quality of life that were not afforded by months of conservative care. The percentage of patients utilizing narcotics at the 5-year follow-up visit was 39%, less than half the percentage of patients who had used narcotics as part of failed conservative treatment.
Data from the current study clearly show that in an appropriately selected patient, spinal surgery is a very good treatment option for improving function and ameliorating disability and pain through at least 5 years of follow-up and is beneficial to the patient according to multiple parameters for life quality. Our study hypothesis was supported in that TDR surgery using the ProDisc-L proved to be noninferior to fusion at 2 years posttreatment, and success was maintained through a minimum of 5 years after surgery.
Conclusions
Measures of disability, pain, and neurological status all improved more quickly in TDR patients than in the fusion group and were similarly improved from baseline in both groups at 5 years posttreatment. Furthermore, narcotics use decreased and recreational status increased in both treatment groups as compared with baseline. The 5-year results of this study support either TDR or fusion surgery as a predictable and lasting treatment option to improve pain and function in properly selected patients with mechanical DDD. These improvements occurred dramatically immediately after surgery and were maintained through the follow-up period.
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